Asunaprevir/daclatasvirImmunoallegic events: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2015年 / 1581卷 / 1期

关键词：

D O I：

10.1007/s40278-015-11737-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：47 / 47

相关论文

共 50 条

[21] CarfilzomibCardiovascular events and renal impairment: 2 case reports
Reactions Weekly, 2017, 1677 (1) : 80 - 80
[22] Cladribine/pentostatinCutaneous adverse events: 2 case reports
Reactions Weekly, 2019, 1751 (1) : 100 - 100
[23] Heparin/tinzaparin sodiumBleeding events: 2 case reports
Reactions Weekly, 2018, 1692 (1) : 156 - 156
[24] EpoprostenolAcute adverse cardiovascular events: 2 case reports
Reactions Weekly, 2017, 1671 (1) : 181 - 181
[25] Dactinomycin/methotrexateGastrointestinal and haematologic adverse events: 2 case reports
Reactions Weekly, 2019, 1765 (1) : 136 - 136
[26] TrastuzumabNon-myopathic cardiac events: 2 case reports
Reactions Weekly, 2007, 1146-1147 (1) : 25 - 25
[27] PembrolizumabFatal immune related adverse events: 2 case reports
Reactions Weekly, 2019, 1765 (1) : 261 - 261
[28] PembrolizumabImmune-related adverse events: 2 case reports
Reactions Weekly, 2020, 1789 (1) : 220 - 220
[29] RituximabCardiovascular events and cytokine release syndrome: 2 case reports
Reactions Weekly, 2014, 1493 (1) : 39 - 39
[30] Dapsone/rasburicaseHaemolytic events associated with anaemia: 2 case reports
Reactions Weekly, 2022, 1918 (1) : 182 - 182

← 1 2 3 4 5 →